Opus Genetics, Inc.

NasdaqCM:IRD Stock Report

Market Cap: US$42.4m

Opus Genetics Management

Management criteria checks 2/4

Opus Genetics' CEO is George Magrath, appointed in Nov 2023, has a tenure of 1.5 years. total yearly compensation is $889.24K, comprised of 64.7% salary and 35.3% bonuses, including company stock and options. directly owns 1.52% of the company’s shares, worth $644.37K. The average tenure of the management team and the board of directors is 1.4 years and 4.5 years respectively.

Key information

George Magrath

Chief executive officer

US$889.2k

Total compensation

CEO salary percentage64.7%
CEO tenure1.5yrs
CEO ownership1.5%
Management average tenure1.4yrs
Board average tenure4.5yrs

Recent management updates

Recent updates

Slammed 25% Opus Genetics, Inc. (NASDAQ:IRD) Screens Well Here But There Might Be A Catch

Apr 09
Slammed 25% Opus Genetics, Inc. (NASDAQ:IRD) Screens Well Here But There Might Be A Catch

Analyst Forecasts For Ocuphire Pharma, Inc. (NASDAQ:OCUP) Are Surging Higher

Aug 19
Analyst Forecasts For Ocuphire Pharma, Inc. (NASDAQ:OCUP) Are Surging Higher

Investors Still Aren't Entirely Convinced By Ocuphire Pharma, Inc.'s (NASDAQ:OCUP) Revenues Despite 30% Price Jump

Jul 24
Investors Still Aren't Entirely Convinced By Ocuphire Pharma, Inc.'s (NASDAQ:OCUP) Revenues Despite 30% Price Jump

Companies Like Ocuphire Pharma (NASDAQ:OCUP) Are In A Position To Invest In Growth

Jul 12
Companies Like Ocuphire Pharma (NASDAQ:OCUP) Are In A Position To Invest In Growth

Slammed 26% Ocuphire Pharma, Inc. (NASDAQ:OCUP) Screens Well Here But There Might Be A Catch

May 02
Slammed 26% Ocuphire Pharma, Inc. (NASDAQ:OCUP) Screens Well Here But There Might Be A Catch

Ocuphire Pharma, Inc. (NASDAQ:OCUP) Shares May Have Slumped 26% But Getting In Cheap Is Still Unlikely

Mar 15
Ocuphire Pharma, Inc. (NASDAQ:OCUP) Shares May Have Slumped 26% But Getting In Cheap Is Still Unlikely

Analysts Just Shaved Their Ocuphire Pharma, Inc. (NASDAQ:OCUP) Forecasts Dramatically

May 20
Analysts Just Shaved Their Ocuphire Pharma, Inc. (NASDAQ:OCUP) Forecasts Dramatically

Ocuphire Pharma, Inc. Just Beat Revenue Estimates By 42%

Apr 02
Ocuphire Pharma, Inc. Just Beat Revenue Estimates By 42%

We're Keeping An Eye On Ocuphire Pharma's (NASDAQ:OCUP) Cash Burn Rate

Jan 27
We're Keeping An Eye On Ocuphire Pharma's (NASDAQ:OCUP) Cash Burn Rate

We Think Ocuphire Pharma (NASDAQ:OCUP) Needs To Drive Business Growth Carefully

Oct 08
We Think Ocuphire Pharma (NASDAQ:OCUP) Needs To Drive Business Growth Carefully

Ocuphire completes patient enrollment for phase 2 trial of diabetic retinopathy treatment

Sep 08

Ocuphire Pharma GAAP EPS of -$0.25 beats by $0.08

Aug 12

Ocuphire extends IP rights for lead candidate with new U.S. patent

Aug 03

Ocuphire gets new U.S. patent for its oral drug candidate APX3330 for use in diabetics

Jun 29

We're Keeping An Eye On Ocuphire Pharma's (NASDAQ:OCUP) Cash Burn Rate

Jun 24
We're Keeping An Eye On Ocuphire Pharma's (NASDAQ:OCUP) Cash Burn Rate

CEO Compensation Analysis

How has George Magrath's remuneration changed compared to Opus Genetics's earnings?
DateTotal CompensationSalaryCompany Earnings
Dec 31 2024US$889kUS$575k

-US$58m

Sep 30 2024n/an/a

-US$27m

Jun 30 2024n/an/a

-US$14m

Mar 31 2024n/an/a

-US$11m

Dec 31 2023US$3mUS$96k

-US$10m

Compensation vs Market: George's total compensation ($USD889.24K) is above average for companies of similar size in the US market ($USD682.63K).

Compensation vs Earnings: George's compensation has been consistent with company performance over the past year.

CEO

George Magrath (40 yo)

1.5yrs

Tenure

US$889,238

Compensation

Mr. George Magrath, MD, MBA, Ms. serves as CEO & Director of Opus Genetics, Inc. (formerly known as Ocuphire Pharma, Inc.) since November 1, 2023. He was an Analyst at Edison Investment Research Limited si...

Leadership Team

NamePositionTenureCompensationOwnership
George Magrath
CEO & Director1.5yrsUS$889.24k1.52%
$ 644.4k
Benjamin Yerxa
President & Directorless than a yearno data0.022%
$ 9.3k
Nirav Suresh Jhaveri
Chief Financial Officer1.3yrsUS$1.39m0.081%
$ 34.3k
Ashwath Jayagopal
Chief Scientific & Development Officer1.3yrsUS$1.24m0.037%
$ 15.9k
Joseph Schachle
Chief Operating Officer1.5yrsno data0.0044%
$ 1.9k
Bernhard Hoffmann
Senior Vice President of Corporate Development & Secretaryno dataUS$789.92k0.26%
$ 109.7k
Amy Zaremba Rabourn
Senior Vice President of Financeno dataUS$789.92k0.047%
$ 19.7k
Bindu Manne
Head of Market Development & Commercialization3.3yrsno datano data
Erik Sims
Director & Corporate Controllerno datano datano data

1.4yrs

Average Tenure

46yo

Average Age

Experienced Management: IRD's management team is not considered experienced ( 1.4 years average tenure), which suggests a new team.

Board Members

NamePositionTenureCompensationOwnership
George Magrath
CEO & Director1.5yrsUS$889.24k1.52%
$ 644.4k
Benjamin Yerxa
President & Directorno datano data0.022%
$ 9.3k
James S. Manuso
Independent Director4.5yrsUS$184.43k0.31%
$ 131.5k
Adrienne Graves
Independent Directorless than a yearUS$192.82kno data
David Boyer
Member of Medical Advisory Boardno datano datano data
Richard Rodgers
Independent Director4.5yrsUS$267.48k0.53%
$ 222.9k
Susan Benton
Independent Director4.5yrsUS$176.39k0.31%
$ 130.5k
Cameron Gallagher
Independent Chairman4.5yrsUS$219.61k1.89%
$ 802.9k
Sean Ainsworth
Lead Independent Director4.5yrsUS$200.22k0.10%
$ 44.0k
Jean Bennett
Directorless than a yearUS$325.82k0.075%
$ 31.7k
Arshad Khanani
Member of Medical Advisory Board1.2yrsno datano data
Mark Pennesi
Member of Medical Advisory Boardno datano datano data

4.5yrs

Average Tenure

57.5yo

Average Age

Experienced Board: IRD's board of directors are considered experienced (4.5 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/05/07 01:31
End of Day Share Price 2025/05/07 00:00
Earnings2024/12/31
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Opus Genetics, Inc. is covered by 4 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
James MolloyAlliance Global Partners
Gum-Ming LoweCraig-Hallum Capital Group LLC
Matthew CaufieldH.C. Wainwright & Co.